
Glenn S Bauman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4923489/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet, The, 2019, 393, 2051-2058.	13.7	1,333
2	Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial. Journal of Clinical Oncology, 2014, 32, 3810-3816.	1.6	894
3	Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial. Journal of Clinical Oncology, 2004, 22, 1583-1588.	1.6	757
4	Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. Journal of Clinical Oncology, 2020, 38, 2830-2838.	1.6	683
5	Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 1884-1890.	1.6	521
6	Prostate volume contouring: A 3D analysis of segmentation using 3DTRUS, CT, and MR. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1238-1247.	0.8	224
7	Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. International Journal of Radiation Oncology Biology Physics, 1999, 45, 923-929.	0.8	204
8	68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Focus, 2018, 4, 686-693.	3.1	195
9	Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer, 2019, 19, 816.	2.6	165
10	A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. International Journal of Radiation Oncology Biology Physics, 1994, 29, 835-839.	0.8	156
11	Radiopharmaceuticals for the palliation of painful bone metastases—a systematic review. Radiotherapy and Oncology, 2005, 75, 258.E1-258.E13.	0.6	148
12	Adaptive Radiotherapy Planning on Decreasing Gross Tumor Volumes as Seen on Megavoltage Computed Tomography Images. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1316-1322.	0.8	146
13	18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer and Prostatic Diseases, 2012, 15, 45-55.	3.9	139
14	Reirradiation of primary CNS tumors. International Journal of Radiation Oncology Biology Physics, 1996, 36, 433-441.	0.8	128
15	Boosting imaging defined dominant prostatic tumors: A systematic review. Radiotherapy and Oncology, 2013, 107, 274-281.	0.6	115
16	Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910. Journal of Clinical Oncology, 2015, 33, 332-339.	1.6	113
17	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1963-1996.	1.6	107
18	Prostate Histopathology: Learning Tissue Component Histograms for Cancer Detection and Classification. IEEE Transactions on Medical Imaging, 2013, 32, 1804-1818.	8.9	96

#	Article	IF	CITATIONS
19	Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2022, 12, 265-282.	2.1	90
20	Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer. International Journal of Radiation Oncology Biology Physics, 1998, 42, 319-324.	0.8	84
21	Ki-67: a prognostic factor for low-grade glioma?. International Journal of Radiation Oncology Biology Physics, 2002, 52, 996-1001.	0.8	82
22	Adult Supratentorial Low-Grade Glioma: Long-Term Experience at a Single Institution. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1401-1407.	0.8	74
23	Evaluation of image-guided radiation therapy (IGRT) technologies and their impact on the outcomes of hypofractionated prostate cancer treatments: A radiobiologic analysis. International Journal of Radiation Oncology Biology Physics, 2006, 64, 289-300.	0.8	71
24	Helical tomotherapy for craniospinal radiation. British Journal of Radiology, 2005, 78, 548-552.	2.2	70
25	Prostate contouring uncertainty in megavoltage computed tomography images acquired with a helical tomotherapy unit during image-guided radiation therapy. International Journal of Radiation Oncology Biology Physics, 2006, 65, 595-607.	0.8	68
26	Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound. Cancer Research, 2007, 67, 2830-2839.	0.9	65
27	Planning evaluation of radiotherapy for complex lung cancer cases using helical tomotherapy. Physics in Medicine and Biology, 2004, 49, 3675-3690.	3.0	64
28	A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 856-862.	0.8	63
29	Prostate: Registration of Digital Histopathologic Images to in Vivo MR Images Acquired by Using Endorectal Receive Coil. Radiology, 2012, 263, 856-864.	7.3	62
30	Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. Journal of Neuro-Oncology, 2012, 107, 395-405.	2.9	61
31	Prospective, Multisite, International Comparison of ¹⁸ F-Fluoromethylcholine PET/CT, Multiparametric MRI, and ⁶⁸ Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes. Journal of Nuclear Medicine. 2019. 60. 794-800.	5.0	61
32	Tomotherapy planning of small brain tumours. Radiotherapy and Oncology, 2005, 74, 49-52.	0.6	59
33	Comparison of advanced irradiation techniques with photons for benign intracranial tumours. Radiotherapy and Oncology, 2006, 80, 268-273.	0.6	59
34	Registration of prostate histology images to ex vivo MR images via strandâ€shaped fiducials. Journal of Magnetic Resonance Imaging, 2012, 36, 1402-1412.	3.4	58
35	Inter- and Intrafraction Uncertainty in Prostate Bed Image-Guided Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 84, 402-407.	0.8	54
36	Intensity-modulated arc therapy for treatment of high-risk endometrial malignancies. International Journal of Radiation Oncology Biology Physics, 2005, 61, 830-841.	0.8	51

#	Article	IF	CITATIONS
37	A Prospective Evaluation of Helical Tomotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 68, 632-641.	0.8	51
38	Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. Prostate Cancer and Prostatic Diseases, 2008, 11, 40-45.	3.9	51
39	Image-guided adaptive radiation therapy (IGART): Radiobiological and dose escalation considerations for localized carcinoma of the prostate. Medical Physics, 2005, 32, 2193-2203.	3.0	49
40	On the performances of Intensity Modulated Protons, RapidArc and Helical Tomotherapy for selected paediatric cases. Radiation Oncology, 2009, 4, 2.	2.7	49
41	Neurocytomas: Long-term experience of a single institution. Neuro-Oncology, 2011, 13, 943-949.	1.2	48
42	Phase I Trial of Simultaneous In-Field Boost With Helical Tomotherapy for Patients With One to Three Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1128-1133.	0.8	47
43	TRIM59, a novel multiple cancer biomarker for immunohistochemical detection of tumorigenesis. BMJ Open, 2012, 2, e001410.	1.9	47
44	Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2019, 105, 943-947.	0.8	46
45	Technology assessment of automated atlas based segmentation in prostate bed contouring. Radiation Oncology, 2011, 6, 110.	2.7	45
46	Low-grade gliomas in children: tumor volume response to radiation. Journal of Neurosurgery, 1998, 88, 969-974.	1.6	43
47	A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 546-555.	0.8	42
48	Postoperative radiotherapy for stage I/II seminoma: results for 212 patients. International Journal of Radiation Oncology Biology Physics, 1998, 42, 313-317.	0.8	41
49	Dosimetric evaluation of daily rigid and nonrigid geometric correction strategies during on-line image-guided radiation therapy (IGRT) of prostate cancer. Medical Physics, 2006, 34, 352-365.	3.0	41
50	Simultaneous Infield Boost With Helical Tomotherapy for Patients With 1 to 3 Brain Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 38-44.	1.3	41
51	Extended Followup Oncologic Outcome of Randomized Trial Between Cryoablation and External Beam Therapy for Locally Advanced Prostate Cancer (T2c-T3b). Journal of Urology, 2012, 188, 1170-1175.	0.4	40
52	Target margins in radiotherapy of prostate cancer. British Journal of Radiology, 2016, 89, 20160312.	2.2	39
53	A comparison of prostate IMRT and helical tomotherapy class solutions. Radiotherapy and Oncology, 2006, 80, 374-377.	0.6	37
54	A Phase II Trial of Arc-Based Hypofractionated Intensity-Modulated Radiotherapy in Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1306-1315.	0.8	37

#	Article	IF	CITATIONS
55	Effects of radiation on a threeâ€dimensional model of malignant glioma invasion. International Journal of Developmental Neuroscience, 1999, 17, 643-651.	1.6	36
56	Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy. Clinical and Translational Oncology, 2012, 14, 150-156.	2.4	36
57	A Multiphase Validation of Atlas-Based Automatic and Semiautomatic Segmentation Strategies for Prostate MRI. International Journal of Radiation Oncology Biology Physics, 2013, 85, 95-100.	0.8	36
58	Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 1999, 45, 291-295.	0.8	35
59	A pooled analysis of arc-based image-guided simultaneous integrated boost radiation therapy for oligometastatic brain metastases. Radiotherapy and Oncology, 2012, 102, 180-186.	0.6	35
60	Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2020, 21, 9054.	4.1	32
61	Nontraumatic Osteonecrosis After Chemotherapy for Testicular Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 603-606.	1.3	31
62	Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer. Radiation Oncology, 2008, 3, 1.	2.7	31
63	CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933. Journal of Neuro-Oncology, 2016, 126, 327-336.	2.9	31
64	3D prostate histology image reconstruction: Quantifying the impact of tissue deformation and histology section location. Journal of Pathology Informatics, 2013, 4, 31.	1.7	29
65	A Novel Salvage Option for Local Failure in Prostate Cancer, Reirradiation Using External Beam or Stereotactic Radiation Therapy: Systematic Review and Meta-Analysis. Advances in Radiation Oncology, 2020, 5, 965-977.	1.2	29
66	The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer – a systematic review. Radiotherapy and Oncology, 2002, 64, 239-250.	0.6	26
67	Toward Prostate Cancer Contouring Guidelines on Magnetic Resonance Imaging: Dominant Lesion Gross and Clinical Target Volume Coverage Via Accurate Histology Fusion. International Journal of Radiation Oncology Biology Physics, 2016, 96, 188-196.	0.8	26
68	The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy. Prostate Cancer and Prostatic Diseases, 2015, 18, 358-364.	3.9	24
69	A threeâ€gene DNA methylation biomarker accurately classifies early stage prostate cancer. Prostate, 2019, 79, 1705-1714.	2.3	24
70	The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of ¹⁸ F-Fluoromethylcholine or ⁶⁸ Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. Journal of Nuclear Medicine, 2019, 60, 1253-1258.	5.0	24
71	Schedule for CT image guidance in treating prostate cancer with helical tomotherapy. British Journal of Radiology, 2010, 83, 241-251.	2.2	22
72	Dynamic perfusion CT in brain tumors. European Journal of Radiology, 2015, 84, 2386-2392.	2.6	22

#	Article	IF	CITATIONS
73	Accuracy Validation of an Automated Method for Prostate Segmentation in Magnetic Resonance Imaging. Journal of Digital Imaging, 2017, 30, 782-795.	2.9	22
74	Histologic tissue components provide major cues for machine learning-based prostate cancer detection and grading on prostatectomy specimens. Scientific Reports, 2020, 10, 9911.	3.3	22
75	Effects of radiation on a model of malignant glioma invasion. Journal of Neuro-Oncology, 1999, 44, 223-231.	2.9	21
76	Systematic review of brain metastases prognostic indices. Practical Radiation Oncology, 2013, 3, 101-106.	2.1	21
77	[18F]-DCFPyL Positron Emission Tomography/Magnetic Resonance Imaging for Localization of Dominant Intraprostatic Foci: First Experience. European Urology Focus, 2018, 4, 702-706.	3.1	21
78	The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2023, 26, 240-248.	3.9	21
79	Segmentation and leaf sequencing for intensity modulated arc therapy. Medical Physics, 2007, 34, 1779-1788.	3.0	20
80	Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas. Seminars in Radiation Oncology, 2001, 11, 170-180.	2.2	19
81	A phase II multi-institutional study assessing simultaneous in-field boost helical tomotherapy for 1-3 brain metastases. Radiation Oncology, 2012, 7, 42.	2.7	18
82	The Effect of Scan Duration on the Measurement of Perfusion Parameters in CT Perfusion Studies ofÂBrain Tumors. Academic Radiology, 2013, 20, 59-65.	2.5	18
83	Detecting tumor progression in glioma: current standards and new techniques. Expert Review of Anticancer Therapy, 2016, 16, 1177-1188.	2.4	18
84	Cost-effectiveness of prophylactic cranial irradiation with hippocampal avoidance in limited stage small cell lung cancer. Radiotherapy and Oncology, 2017, 122, 411-415.	0.6	18
85	Simplified intensity-modulated arc therapy for dose escalated prostate cancer radiotherapy. Medical Dosimetry, 2004, 29, 18-25.	0.9	17
86	Long-Term Oncologic Outcomes of Salvage Cryoablation for Radio-Recurrent Prostate Cancer. Journal of Urology, 2016, 196, 1105-1111.	0.4	17
87	Impact of geometric uncertainties on evaluation of treatment techniques for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 426-436.	0.8	16
88	3D Conformal Radiotherapy and Cisplatin for Recurrent Malignant Glioma. Canadian Journal of Neurological Sciences, 2008, 35, 57-64.	0.5	16
89	Molecular Targeted Enhanced Ultrasound Imaging of Flk1 Reveals Diagnosis and Prognosis Potential in a Genetically Engineered Mouse Prostate Cancer Model. Molecular Imaging, 2009, 8, 7290.2009.00020.	1.4	16
90	Propensity-score matched pair comparison of whole brain with simultaneous in-field boost radiotherapy and stereotactic radiosurgery. Radiotherapy and Oncology, 2013, 106, 206-209.	0.6	16

#	Article	IF	CITATIONS
91	Spatially varying accuracy and reproducibility of prostate segmentation in magnetic resonance images using manual and semiautomated methods. Medical Physics, 2014, 41, 113503.	3.0	16
92	Management of High-Grade Gliomas in the Elderly. Seminars in Radiation Oncology, 2014, 24, 279-288.	2.2	16
93	Survival prediction in high-grade gliomas using CT perfusion imaging. Journal of Neuro-Oncology, 2015, 123, 93-102.	2.9	16
94	Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts. Advances in Radiation Oncology, 2020, 5, 212-220.	1.2	16
95	Effect of ¹⁸ F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial. Radiology, 2022, 303, 414-422.	7.3	16
96	Evaluation of imageâ€guidance strategies with helical tomotherapy for localised prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2011, 55, 220-228.	1.8	15
97	Experimental assessments of intrafractional prostate motion on sequential and simultaneous boost to a dominant intraprostatic lesion. Medical Physics, 2012, 39, 1505-1517.	3.0	15
98	A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis. Advances in Radiation Oncology, 2019, 4, 668-673.	1.2	15
99	Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in Ontario, Canada. Radiotherapy and Oncology, 2020, 152, 42-48.	0.6	15
100	Beyond Oligometastases. International Journal of Radiation Oncology Biology Physics, 2020, 107, 253-256.	0.8	15
101	Online advertising and marketing claims by providers of proton beam therapy: are they guideline-based?. Radiation Oncology, 2018, 13, 43.	2.7	14
102	Molecular targeted enhanced ultrasound imaging of flk1 reveals diagnosis and prognosis potential in a genetically engineered mouse prostate cancer model. Molecular Imaging, 2009, 8, 209-20.	1.4	14
103	Primary intracerebral osteosarcoma: a case report. Journal of Neuro-Oncology, 1997, 32, 209-213.	2.9	13
104	Bub1 Up-Regulation and Hyperphosphorylation Promote Malignant Transformation in SV40 Tag–Induced Transgenic Mouse Models. Molecular Cancer Research, 2006, 4, 957-969.	3.4	13
105	Dosimetric and Radiobiological Consequences of Computed Tomography–Guided Adaptive Strategies for Intensity Modulated Radiation Therapy of the Prostate. International Journal of Radiation Oncology Biology Physics, 2013, 87, 874-880.	0.8	13
106	Initial Investigation into Microbleeds and White Matter Signal Changes following Radiotherapy for Low-Grade and Benign Brain Tumors Using Ultra-High-Field MRI Techniques. American Journal of Neuroradiology, 2017, 38, 2251-2256.	2.4	13
107	Ablative radiation therapy to restrain everything safely treatable (ARREST): study protocol for a phase I trial treating polymetastatic cancer with stereotactic radiotherapy. BMC Cancer, 2021, 21, 405.	2.6	13
108	Comparative planning evaluation of intensity-modulatedradiotherapy techniques for complex lung cancer cases. Radiotherapy and Oncology, 2006, 78, 169-176.	0.6	12

#	Article	IF	CITATIONS
109	Patient- and family-centered care: a qualitative exploration of oncologist perspectives. Supportive Care in Cancer, 2017, 25, 213-219.	2.2	12
110	Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer. Canadian Urological Association Journal, 2020, 15, 162-172.	0.6	12
111	Is Remote Learning as Effective as In-Person Learning for Contouring Education? A Prospective Comparison of Face-to-Face versus Online Delivery of the Anatomy and Radiology Contouring Bootcamp. International Journal of Radiation Oncology Biology Physics, 2022, 112, 590-599.	0.8	12
112	Optimization of tomotherapy treatment planning for patients with bilateral hip prostheses. Radiation Oncology, 2014, 9, 43.	2.7	11
113	Improving Quantitative CT Perfusion Parameter Measurements Using Principal Component Analysis. Academic Radiology, 2014, 21, 624-632.	2.5	11
114	Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR Images. Biomarkers in Cancer, 2016, 8s2, BIC.S31801.	3.6	11
115	Extreme hypofractionation for high-risk prostate cancer: Dosimetric correlations with rectal bleeding. Practical Radiation Oncology, 2017, 7, e457-e462.	2.1	11
116	Bihemispheric malignant glioma: one size does not fit all. Journal of Neuro-Oncology, 1998, 38, 83-89.	2.9	10
117	Dosimetric Comparison of Intensity-Modulated Radiosurgery and Helical Tomotherapy for the Treatment of Multiple Intracranial Metastases. Technology in Cancer Research and Treatment, 2009, 8, 361-367.	1.9	10
118	Impact of ¹⁸ F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer. Radiology, 2022, 304, 600-608.	7.3	10
119	Systematic review of fractionated brain metastases radiotherapy. Journal of Radiation Oncology, 2014, 3, 29-41.	0.7	9
120	Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial. BMC Cancer, 2020, 20, 978.	2.6	9
121	Novel Application of Helical Tomotherapy in Whole Skull Palliative Radiotherapy. Medical Dosimetry, 2008, 33, 282-285.	0.9	8
122	Characterization of clinical human prostate cancer lesions using 3.0â€T sodium MRI registered to Gleasonâ€graded wholeâ€mount histopathology. Journal of Magnetic Resonance Imaging, 2019, 49, 1409-1419.	3.4	8
123	Histologic validation of auto-contoured dominant intraprostatic lesions on [18F] DCFPyL PSMA-PET imaging. Radiotherapy and Oncology, 2020, 152, 34-41.	0.6	8
124	Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician's guide. Expert Review of Anticancer Therapy, 2021, 21, 641-655.	2.4	8
125	A pilot study of regional participation in a videoconferenced multidisciplinary genitourinary tumor board. Canadian Journal of Urology, 2005, 12, 2532-6.	0.0	8
126	Asymmetric fan beams (AFB) for improvement of the craniocaudal dose distribution in helical tomotherapy delivery. Medical Physics, 2004, 31, 2443-2448.	3.0	7

#	Article	IF	CITATIONS
127	In regard to Fiorino et al.: rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer (Int J Radiat Oncol Biol Phys 2003;57:953–962). International Journal of Radiation Oncology Biology Physics, 2004, 59, 912-914.	0.8	7
128	Consistency Check of Planned Adaptive® Option on Helical Tomotherapy. Technology in Cancer Research and Treatment, 2008, 7, 425-432.	1.9	7
129	Categorizing segmentation quality using a quantitative quality assurance algorithm. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 668-678.	1.8	7
130	Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant glioma. Journal of Medical Radiation Sciences, 2014, 61, 4-13.	1.5	7
131	Unshielded asymmetric transmit-only and endorectal receive-only radiofrequency coil for ²³ Na MRI of the prostate at 3 tesla. Journal of Magnetic Resonance Imaging, 2015, 42, 436-445.	3.4	7
132	Evaluation of CT Perfusion Biomarkers of Tumor Hypoxia. PLoS ONE, 2016, 11, e0153569.	2.5	7
133	18F-DCFPyL PET/CT in Oncocytoma. Clinical Nuclear Medicine, 2018, 43, 921-924.	1.3	7
134	Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging. Advances in Radiation Oncology, 2021, 6, 100553.	1.2	7
135	Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI. Clinical and Translational Radiation Oncology, 2022, 32, 41-47.	1.7	7
136	Fractionated Radiotherapy Techniques. Neurosurgery Clinics of North America, 2006, 17, 99-110.	1.7	6
137	Psychometric properties of a prostate cancer radiation late toxicity questionnaire. Health and Quality of Life Outcomes, 2007, 5, 29.	2.4	6
138	Radiosurgery scope of practice in Canada: A report of the Canadian association of radiation oncology (CARO) radiosurgery advisory committee. Radiotherapy and Oncology, 2010, 95, 122-128.	0.6	6
139	Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. Canadian Urological Association Journal, 2016, 10, 90.	0.6	6
140	Re: New radiotherapy technologies for meningiomas: 3D conformal radiotherapy? Radiosurgery? Sterotactic radiotherapy? Intensity modulated radiotherapy? Proton beam radiotherapy? Spot scanning proton radiation therapy? Or nothing at all? [Radiother Oncol 2004;71(3):247–249]. Radiotherapy and Oncology, 2004, 73, 251-252.	0.6	5
141	3D reconstruction of prostate histology based on quantified tissue cutting and deformation parameters. Proceedings of SPIE, 2012, , .	0.8	5
142	Apparent transverse relaxation () on <scp>MRI</scp> as a method to differentiate treatment effect (pseudoprogression) versus progressive disease in chemoradiation for malignant glioma. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 224-231.	1.8	5
143	Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada. Frontiers in Oncology, 2021, 11, 722430.	2.8	5
144	Validation of Direct Registration of Whole-Mount Prostate Digital Histopathology to ex vivo MR Images. Lecture Notes in Computer Science, 2011, , 134-145.	1.3	5

#	Article	IF	CITATIONS
145	PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial. BMC Cancer, 2022, 22, 251.	2.6	5
146	A simple technique for craniospinal radiotherapy in the supine position. Radiotherapy and Oncology, 2006, 80, 394.	0.6	4
147	Tissue block MRI for slice orientation-independent registration of digital histology images to ex vivo MRI of the prostate. , 2011, , .		4
148	Assessment and improvement of radiation oncology trainee contouring ability utilizing consensus-based penalty metrics. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 679-688.	1.8	4
149	The Singularity is Near(ish): Emerging Applications of Artificial Intelligence in Prostate Cancer Management. European Urology, 2020, 77, 293-295.	1.9	4
150	Development, Implementation, and Initial Participant Feedback of an Online Anatomy and Radiology Contouring Bootcamp in Radiation Oncology. Journal of Medical Education and Curricular Development, 2021, 8, 238212052110377.	1.5	4
151	Can Polymetastatic Disease Be ARRESTed Using SABR? A Dosimetric Feasibility Study to Inform Development of a Phase 1 Trial. Advances in Radiation Oncology, 2021, 6, 100734.	1.2	4
152	Radiotherapy for Pediatric Central Nervous System Tumors: A Regional Cancer Centre Experience. Journal of Neuro-Oncology, 2004, 68, 285-294.	2.9	3
153	Serial megavoltage CT imaging during external beam radiotherapy for non–small-cell lung cancer: in regard to Kupelian et al. (Int J Radiat Oncol Biol Phys 2005;630:1024–1028). International Journal of Radiation Oncology Biology Physics, 2006, 64, 328.	0.8	3
154	Toward quantitative digital histopathology for prostate cancer: comparison of inter-slide interpolation methods for tumour measurement. Proceedings of SPIE, 2013, , .	0.8	3
155	In Regard to Lee. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1212-1213.	0.8	3
156	Postediting prostate magnetic resonance imaging segmentation consistency and operator time using manual and computer-assisted segmentation: multiobserver study. Journal of Medical Imaging, 2016, 3, 046002.	1.5	3
157	Lessons learned from reirradiation of recurrent skull base meningioma: A case report and review of the literature. Advances in Radiation Oncology, 2017, 2, 1-5.	1.2	3
158	The Utility of Penile Bulb Contouring to Localise the Prostate Apex as Compared to Urethrography. Journal of Medical Imaging and Radiation Sciences, 2018, 49, 76-83.	0.3	3
159	A multiobserver study investigating the effectiveness of prostatic multiparametric magnetic resonance imaging to dose escalate corresponding histologic lesions using high-dose-rate brachytherapy. Brachytherapy, 2021, 20, 601-610.	0.5	3
160	Automatic cancer detection and localization on prostatectomy histopathology images. , 2018, , .		3
161	CT Perfusion Imaging as an Early Biomarker of Differential Response to Stereotactic Radiosurgery in C6 Rat Cliomas. PLoS ONE, 2014, 9, e109781.	2.5	3
162	Simultaneous In-Field Boost for Brain Metastases: In Regard to Lagerwaard etÂal. (Int J Radiat Oncol) Tj ETQq0 0 C	rgBT /Ov 0.8	erlock 10 Tf 2

10

964-965.

#	Article	IF	CITATIONS
163	Pulmonary Tumor Measurements from X-Ray Computed Tomography inÂOne, Two, and Three Dimensions. Academic Radiology, 2011, 18, 1391-1402.	2.5	2
164	American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer. Practical Radiation Oncology, 2021, 11, 163-165.	2.1	2
165	Short-duration dynamic [18F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [18F]DCFPyL PET/MR at 120 minutes. EJNMMI Research, 2021, 11, 107.	2.5	2
166	A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases. Cureus, 2019, 11, e6394.	0.5	2
167	Automatic cancer detection on digital histopathology images of mid-gland radical prostatectomy specimens. Journal of Medical Imaging, 2020, 7, 1.	1.5	2
168	Hippocampus avoidance with fan beam and volumetric arc radiotherapy for base of skull tumours. Journal of Radiotherapy in Practice, 2010, 9, 87-98.	0.5	1
169	3D prostate histology reconstruction: an evaluation of image-based and fiducial-based algorithms. Proceedings of SPIE, 2013, , .	0.8	1
170	Multiparametric MR imaging of prostate cancer foci: assessing the detectability and localizability of Gleason 7 peripheral zone cancers based on image contrasts. , 2014, , .		1
171	Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1–3 metastases. Journal of Neuro-Oncology, 2016, 128, 431-436.	2.9	1
172	Choosing Wisely? "It's Complicated!― Practical Radiation Oncology, 2016, 6, 71-73.	2.1	1
173	Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019:75:285–93. European Urology, 2020, 77, e67-e68.	1.9	1
174	Case – Prostate-specific antigen bounce: A pitfall in prostate-specific membrane antigen positron emission tomography/computed tomography interpretation. Canadian Urological Association Journal, 2021, 15, E620-E621.	0.6	1
175	Development of a computer aided diagnosis model for prostate cancer classification on multi-parametric MRI. , 2018, , .		1
176	Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology. Brachytherapy, 2022, , .	0.5	1
177	Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol. Frontiers in Oncology, 2022, 12, 863848.	2.8	1
178	Simulation for localized prostate cancer: a comparison of urethrography techniques. Medical Dosimetry, 2000, 25, 145-148.	0.9	0
179	Short Communication: Conformal Therapy for Peri-Ventricular Brain Tumors: Is Target Volume Deformation an Issue?. Medical Dosimetry, 2008, 33, 78-80.	0.9	0
180	Co-registration Framework for Histology-registration-based Validation of Fused Multimodality Prostate Cancer Imaging. , 2011, , .		0

#	Article	IF	CITATIONS
181	In regard to Vargo et al: "Early Clinical Outcomes for 3 Radiation Techniques for Brain Metastases: Focal Versus Whole-Brain". Practical Radiation Oncology, 2012, 2, 155.	2.1	0
182	Accuracy and variability of tumor burden measurement on multi-parametric MRI. , 2014, , .		0
183	A dimensionless dynamic contrast enhanced MRI parameter for intra-prostatic tumour target volume delineation: initial comparison with histology. , 2014, , .		Ο
184	Metastatic brain cancer: prediction of response to whole-brain helical tomotherapy with simultaneous intralesional boost for metastatic disease using quantitative MR imaging features. , 2014, , .		0
185	In Reply to Kishan etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1163.	0.8	0
186	Optimization of brain metastases radiotherapy with TomoHDA. Medical Dosimetry, 2017, 42, 53-56.	0.9	0
187	Searching for wisdom in oncology care: A scoping review. Palliative and Supportive Care, 2017, 15, 384-400.	1.0	0
188	The "Dirty Harry―Approach. International Journal of Radiation Oncology Biology Physics, 2017, 99, 8.	0.8	0
189	Prostate specific membrane antigen positron emission tomography for lesion-directed high-dose-rate brachytherapy dose escalation. Physics and Imaging in Radiation Oncology, 2021, 19, 102-107.	2.9	0
190	Re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374–82. European Urology, 2021, 80, e77-e78.	1.9	0
191	Rapid visual field progression in a patient with glaucoma as the presenting manifestation of sarcoidosis. American Journal of Ophthalmology Case Reports, 2021, 23, 101132.	0.7	0
192	Implementation and evaluation of an online anatomy, radiology and contouring bootcamp for radiation therapists. Journal of Medical Imaging and Radiation Sciences, 2021, 52, 567-575.	0.3	0
193	On the Way for Patients with Prostate Cancer to the Best Use of PSMA. International Journal of Molecular Sciences, 2022, 23, 2478.	4.1	0